1、Investor Update F.Hoffmann-La Roche Ltd 4070 Basel Switzerland Investor Relations email: Tel.+41 61 68-88880 Fax+41 61 69-10014 1/13 Ad hoc announcement pursuant to Art.53 LR Basel,30 January 2025 Roche reports strong 2024 results with 7%sales growth;fourth quarter marks third straight quarter of 9%

2、growth Group sales grew by 7%1 at constant exchange rates(CER;3%in CHF),driven by strong demand for both medicines and diagnostics.Excluding COVID-19,Group sales increased by 9%.COVID-19 will not adversely impact our results from 2025 onwards.The fourth quarter was the third consecutive quarter of 9

3、%sales growth,highlighting the very positive momentum.Pharmaceuticals Division sales rose by 8%(excluding COVID-19 medicine:9%)on growing demand for newer medicines;top growth drivers were Vabysmo(severe eye diseases),Phesgo(breast cancer),Ocrevus(multiple sclerosis)and Hemlibra(haemophilia A).Diagn

4、ostics Division sales increased by 4%,reflecting the base effect of the sales of COVID-19 tests in the prior-year period;strong momentum in the Diagnostics Divisions base business continued with an increase of 8%due to higher demand for immunodiagnostic,pathology and molecular solutions.Core operati

5、ng profit grew by 14%(8%in CHF),driven by higher sales,improved gross margin and effective cost management;core earnings per share rose by 7%(1%in CHF).Core earnings per share excluding the impact of the resolution of tax disputes in 2023 rose by 12%,exceeding the guidance for 2024.IFRS net income d

6、ecreased by 19%(26%in CHF),mainly due to impairment charges to goodwill related to Flatiron Health and Spark Therapeutics.Operating free cash flow increased by 34%(CER)to CHF 20.1 billion.Highlights:Launch of cobas Mass Spec,a transformative innovation in mass spectrometry EU approval for Vabysmo pr